Agonistic immune checkpoint regulator may harm the heart



Summary

Agonistic immune checkpoint regulators (AICRs), designed to enhance anti-tumor immunity, may pose a risk to the heart. While AICRs like CD40 agonists are showing promise in cancer treatment by boosting T cell activity, studies indicate they can trigger unintended inflammation in the cardiovascular system. This inflammation can lead to myocarditis, heart failure, and other cardiac complications. This highlights the need for careful monitoring of cardiac function in patients receiving AICR therapy, and further research to understand and mitigate these potential cardiotoxic effects, ensuring safer and more effective cancer immunotherapy.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!